Roivant's Lupus Drug Fails Mid-Stage Study, Program Terminated
TL;DR Summary
Roivant's JAK/TYK2 inhibitor, brepocitinib, licensed from Pfizer, failed to achieve statistical significance in a Phase II lupus trial, leading to the discontinuation of its development in the condition. The high placebo rate was blamed for the drug's lack of efficacy.
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
60%
99 → 40 words
Want the full story? Read the original article
Read on Endpoints News